N/A Completed N=14 Randomized Single-blind Other

The Effect of Hypoxia on Type 2 Diabetes and Weight Loss

Type2 Diabetes

Source: ClinicalTrials.gov NCT05147116 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2025

Primary outcomePrimary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1

Summary

The number of people with type 2 diabetes mellitus (T2DM) continuing to rise, this pandemic is expected to reach 700 million people by 2045. T2DM is a metabolic condition characterized by progressive insulin resistance and chronic hyperglycemia (high blood glucose concentrations). Hyperglycaemia increases the risk of both micro- and macrovascular damage, whilst interventions that reduce blood glucose mitigate this risk. Weight loss, achieved through exercise and dietary modification, is effective at reducing hyperglycaemia. However, despite the clear benefits of exercise and weight loss, diverse psychological, sociological and logistical factors can make it difficult for some individuals with T2DM to initiate, or adhere to, these lifestyle interventions. Alternative approaches to treatment are therefore required. The purpose of this research project is to investigate whether 10-days of overnight exposure to moderate hypoxia is effective at improving blood glucose control in individuals with T2DM and to provide insight into the physiological mechanisms responsible for any beneficial effects.

Outcome Measures

Outcome	Result	p-value
PRIMARY Δ Mean AUC (Area Under the Curve) Plasma [Glucose]	-17.7; 54.9	—
SECONDARY Δ Body Mass	0; -0.7	—
SECONDARY Δ Total Minutes of Physical Activity (Light, Moderate, Moderate to Vigorous Physical Activity).	170; 183	—
SECONDARY Δ Sleep Efficiency (Percentage of Time Spent Asleep While in Bed)	88; 86	—
SECONDARY Δ IL-6	1.06; -0.55	—
SECONDARY Δ TNFɑ	0.66; 0.61	—

Eligibility Criteria

Inclusion Criteria

Males and post-menopausal women with T2DM (as diagnosed with the WHO criteria).

Exclusion Criteria

Individuals with contraindications to hypoxic exposure (e.g. obstructive sleep apnoea, extant cardiac conditions or on medications such as SGLT2 inhibitors or PPAR antagonists).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05147116). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.